Bright Minds Biosciences to Present at Upcoming Conferences

Fri, 04 Sep 2026 16:30:00 -0400

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:

EVENT:

Form 6-K BRIGHT MINDS BIOSCIENCES For: Jun 30

Mon, 17 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260817/26934173.html

Form 6-K BRIGHT MINDS BIOSCIENCES For: Jun 30

Mon, 17 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260817/26934173.html

Form SCHEDULE 13G/A BRIGHT MINDS BIOSCIENCES Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26928715.html

Form SCHEDULE 13G/A BRIGHT MINDS BIOSCIENCES Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26928715.html

Form S-8 BRIGHT MINDS BIOSCIENCES

Thu, 13 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260813/26915657.html

Form S-8 BRIGHT MINDS BIOSCIENCES

Thu, 13 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260813/26915657.html

Form SCHEDULE 13G/A BRIGHT MINDS BIOSCIENCES Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:05:00 -0400

si-local-file:///var/storage/secattach/20260812/26911237.html

Form SCHEDULE 13G/A BRIGHT MINDS BIOSCIENCES Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:05:00 -0400

si-local-file:///var/storage/secattach/20260812/26911237.html

Vistagen names neuroscience veteran Douglas Williamson to its board

Fri, 31 Jul 2026 08:30:10 -0400

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, announced the appointment of Douglas J. Williamson, MD, to its board of directors, according to a press release.

Dr. Williamson is currently a CNS drug development consultant and founder of Destiny Biopharm Consulting. He most recently served as chief medical officer of QurAlis Corporation. Before that, he was executive vice president and head of research and development at Acadia Pharmaceuticals, where he led the company's neuroscience pipeline strategy.

Earlier in his career, Dr. Williamson held the role of chief medical officer at Avadel Pharmaceuticals and senior leadership positions at H. Lundbeck A/S, including senior

Vistagen names neuroscience veteran Douglas Williamson to its board

Fri, 31 Jul 2026 08:30:10 -0400

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, announced the appointment of Douglas J. Williamson, MD, to its board of directors, according to a press release.

Earlier in his career, Dr. Williamson held the role of chief medical officer at Avadel Pharmaceuticals and senior leadership positions at H. Lundbeck A/S, including senior

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Fri, 31 Jul 2026 08:30:00 -0400

Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategy

SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J. Williamson, MD, to its Board of Directors (“Board”). Dr. Williamson brings extensive experience leading neuroscience drug development programs from early clinical research through regulatory approval and commercialization.